New drug made available to ALS patients unable to join trials

NCT ID NCT07088159

AVAILABLE Disease control Sponsor: Spinogenix Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This expanded access program offers the drug tazbentetol to adults with ALS who cannot join other clinical studies. Participants take one 300 mg pill by mouth each day. The program aims to check the drug's safety and whether it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tazbentetol (SPG302), a drug taken by mouth once daily
What this could lead to: If it works, this could provide a treatment option for ALS patients who cannot join other clinical trials.
What could go wrong: This is an expanded access program, not a formal trial, so results are limited. The drug's effectiveness and safety are still being studied, and it may not help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS - AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Atlantic Health
AVAILABLE

Summit, New Jersey, 07901, United States

Contact Email: •••••@•••••
Baylor College of Medicine
AVAILABLE

Houston, Texas, 77030, United States
California Pacific Medical Center
AVAILABLE

San Francisco, California, 94109, United States
Cedar-Sinai Medical Center
AVAILABLE

Los Angeles, California, 90048, United States

Contact Email: •••••@•••••
Columbia University Medical Center
AVAILABLE

New York, New York, 10032, United States

Contact Email: •••••@•••••
Dartmouth-Hitchcock Medical Center
AVAILABLE

Lebanon, New Hampshire, 03756, United States
Kaiser Permanente Los Angeles
AVAILABLE

Los Angeles, California, 90027, United States
Mayo Scottsdale
AVAILABLE

Scottsdale, Arizona, 85259, United States
NYU Langone Health
AVAILABLE

New York, New York, 10017, United States
New Mexico VA Health Care System
AVAILABLE

Albuquerque, New Mexico, 87108, United States
Nova Southeastern University
AVAILABLE

Davie, Florida, 33314, United States
Synapticure
AVAILABLE

Chicago, Illinois, 60640, United States

Contact Email: •••••@•••••
Thomas Jefferson University
AVAILABLE

Philadelphia, Pennsylvania, 19107, United States
University of Alabama Birmingham
AVAILABLE

Birmingham, Alabama, 35233, United States
VCU ALS Research Group
AVAILABLE

Henrico, Virginia, 23233, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.